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ABSTRACT: Icodextrin, a glucose polymer, is widely used as an alternative to glucose as the osmotic agent in peritoneal
dialysis (PD). We describe a case of a continuous ambulatory peritoneal dialysis patient who developed severe cuta-
neous hypersensitivity after initiation of icodextrin PD solution. Erythematous skin lesions gradually disappeared after
discontinuation of icodextrin PD solution. Although the safety and efficacy of icodextrin PD solution is well docu-
mented, clinicians should be mindful of the possibility of severe adverse cutaneous reactions to icodextrin PD solu-
tion.
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CASE REPORT
A 85-year-old woman was admitted to our hospital for
severe dyspnea and generalized edema. The patient’s
past history was unremarkable except for valvular heart
disease and hypertension for 20 years for which she did
not seek regular medical advice. On admission, she
complained of severe shortness of breath, orthopnea,
fatigue and generalized edema. Her serum creatinine
level on presentation was 6.1 mg/dL; her previous
serum creatinine 1 month earlier at another hospital
had been 2.6 mg/dL.
On physical examination, the patient’s blood pressure
was 118/40 mm Hg, heart rate was 90 beats/min,
respiratory rate was 25 breaths/min, and she was
afebrile. Cardiovascular examination showed a
paroxysmal atrial tachycardia on electrocardiogram
and her chest x-ray showed significant cardiomegaly
and pulmonary edema. The echocardiography showed
pseudonormalization of left ventricular filling, grade 4
mitral regurgitation, grade 3 aortic regurgitation and
grade 2 tricuspid regurgitation. Ejection fraction was
80%. She was diagnosed as suffering from diastolic
heart failure with valvular heart disease and chronic
renal failure. She was initially treated conservatively
INTRODUCTION
Icodextrin, a starch-derived glucose polymer, has been
developed as an alternative to glucose for use as the
osmotic agent in peritoneal dialysis (PD) for patients
with ultrafiltration failure. Icodextrin PD solution
provides a sustained level of ultrafiltration, and its use
has been associated with improved fluid management
in PD patients. Icodextrin PD solution (Extraneal,
Baxter Heathcare) is currently used worldwide and has
been available for use in Korea since 2001. It is
increasingly used in continuous ambulatory peritoneal
dialysis (CAPD) and automated peritoneal dialysis
(APD) patients. It has been shown to be generally safe
and tolerable, and has proven itself to be clinically
useful in the fluid management of PD patients.
However, an approximately 3-fold increase in the risk
of developing a new skin rash, when compared with
dextrose-based solutions, has been reported, and rare
cases of severe cutaneous hypersensitivity have been
reported in the literature. We report a case of severe
cutaneous hypersensitivity to icodextrin that was
resolved with discontinuation of icodextrin PD
solution, which is to our knowledge the first report in
Korea.
BHypersensitivity to icodextrin in CAPD
with diuretics, an angiotensin II receptor blocker and
a calcium channel blocker. However, symptomatic
relief was not obtained by conventional therapies, and
symptoms of congestive heart failure (CHF) increased
until the patient suffered severe respiratory insufficiency
even at rest. CAPD using standard glucose PD solution
was initiated to remove excess fluid and manage
refractory CHF after 1 month of conservative treat-
ment. The patient’s generalized edema and her
clinical condition improved after initiation of CAPD.
After discharge from hospital, she was maintained on
CAPD using standard glucose PD solutions. A few
months later, she became noncompliant with her low
salt diet and frequently needed exchanges using
hypertonic PD solutions despite the low average
peritoneal transport characteristics. Thus, overnight
exchange using icodextrin-based dialysate (Extraneal,
lot number S05F20042) was prescribed to maintain
euvolemia. The patient complained of pruritus
immediately after infusion of icodextrin PD solution
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Fig. 1 - Erythematous macular rash on both palm (A) and sole
(B) after 2 days of icodextrin dialysis.
Fig. 2 - Erythematous crusted vesicles with pustules on trunk
after 2 days of icodextrin dialysis.
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and started to develop a pruritic erythematous skin
rash which later spread to the whole body after 2 days.
The skin lesion initially started on her palms, soles, and
face (Figs. 1A and B) and then spread to the trunk of
the whole body (Fig. 2). Laboratory findings showed
no signs of infection or inflammation, and PD
effluents at the onset of the symptoms revealed no
signs of peritoneal inflammation (WBC count <10 with
no eosinophils). Skin biopsy on her palm showed basal
vacuolization, interface dermatitis and mild superficial
perivenular lymphocytic infiltration compatible with
erythema multiforme (Fig. 3). Chronology of her
symptoms strongly suggested adverse reaction to
icodextrin, and icodextrin-based PD solution was
discontinued. Conservative treatment using anti-
histamine, topical steroid agent and a low-dose oral
steroid was prescribed, and the erythematous skin rash
and pruritus gradually disappeared within 7 days after
discontinuation of icodextrin. Currently she is
clinically stable without edema using standard glucose
PD solutions. 
DISCUSSION
The safety data from the clinical trials provide evidence
that icodextrin PD solution is a well-tolerated dialysate
with an adverse event profile generally similar to that
of glucose-based solutions, with a few notable
exceptions. Skin rash was a common treatment-related
adverse reaction to icodextrin in various clinical trials
(1, 2). Patients on icodextrin PD solution showed a
higher incidence of rash (10.1%) compared with those
on glucose-based PD solutions for the long-term
(4.6%, p<0.003) (2). The rash related to icodextrin
usually occurred in the first 3 weeks of treatment and
involved the palms and soles and was mild or moderate
in the majority of the patients. However, rare reports
of severe exfoliative or psoriasiform dermatitis
occurring early after initiation of icodextrin dialysis
have been reported in the literature. In those reports
the onset of the severe adverse skin reactions occurred
usually between 4 and 12 days after initiation of
icodextrin PD solution (3-9). In our case, the patient
complained of generalized pruritus immediately after
changing from the glucose-based solution to the
icodextrin PD solution and developed generalized
erythematous skin rash. Her medications had been
unchanged for many weeks, and she had reported no
previous history of allergic reactions to drugs. 
The underlying mechanism of the severe cutaneous
hypersensitivity to icodextrin is still unknown.
Icodextrin is a glucose polymer that is metabolized to
maltose and is structurally similar to the naturally
occurring dextran, which can be responsible for a
variety of allergic reactions including anaphylactoid or
anaphylactic reactions (10, 11). The 2 polymers differ
only in their linkage of glucose molecules: α1,4 for
icodextrin and α1,6 for dextran. Patients who are
chronically exposed to dextran treatment may show
dextran deposition in the skin and peripheral nerves.
This may cause stimulation of the cutaneous nerves
and result in pruritus (12, 13). High titer of dextran
reactive immunoglobulin G can be found in many of
these patients (14), and the proportion of patients who
have allergic reactions can be reduced substantially by
use of hapten inhibition (15). However, no icodextrin
reactive antibodies were demonstrated in previous
cases, and clinical pictures of severe cutaneous
reaction to icodextrin are not compatible with dextran-
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Fig. 3 - Palm skin shows interface dermatitis, basal vacuolization (A, arrow) and mild superficial perivenular lymphocytic infil-
tration (B, arrow) (H & E, ×200).
Hypersensitivity to icodextrin in CAPD
induced anaphylactic reactions. Our case also failed to
demonstrate any cause for adverse skin reactions to
icodextrin. Probably unknown biochemical mechanisms
or an immune response is associated with these
variable clinical manifestations.
The present case is the first report of severe cutaneous
reaction to icodextrin PD solution in Korea. The safety
and efficacy of icodextrin PD solution has been
documented through various clinical trials over the
past decade. However, the possibility of adverse
cutaneous reaction to icodextrin as in this patient
should always be borne in mind. 
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